Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Conference News AHA 2025

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

Michael O'Riordan

November 14, 2025

News Conference News AHA 2025

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

Todd Neale

November 08, 2025

News Conference News ESC 2025

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Michael O'Riordan

September 10, 2025

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

Caitlin E. Cox

August 31, 2025

News Opinion Editor's Corner ESC 2025

What’s Going to Be Hot at ESC Congress 2025?

Michael O'Riordan

August 25, 2025

News

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Michael O'Riordan

May 30, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

Presentation ACC 2024

Bridge-TIMI 73a: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Presenter: Brian Bergmark

April 07, 2024

News Conference News AHA 2022

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

Michael O'Riordan

November 05, 2022

News Daily News

New Biomarker Data Again Draw Eyes to Mineral Oil in REDUCE-IT

Caitlin E. Cox

July 08, 2022

Presentation SCAI 2020

Reduction of Revascularization in Patients with Hypertriglyceridemia with Icosapent Ethyl: Insights from REDUCE-IT REVASC

Presenter: Benjamin E. Peterson

May 21, 2020

News Conference News AHA 2019

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

Todd Neale

November 18, 2019

News Conference News AHA 2018

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Todd Neale

November 10, 2018

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

News Daily News

Nearly Half of Acute MI Patients Under Age 50 May Have Metabolic Syndrome

L.A. McKeown

April 19, 2018

News Daily News

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

Michael O'Riordan

March 09, 2016

News Daily News

新型反义抑制剂能够降低高甘油三酯水平

August 13, 2015

News Daily News

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

August 13, 2015

News Daily News

Novel Antisense Inhibitor Cuts High Triglyceride Levels

August 13, 2015

Presentation

Antisense Inhibition of Apolipoprotein C-III in Patients With Hypertriglyceridemia

Presenter: D. Gaudet

August 12, 2015

Advertisement

Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia

CRISPR-Cas9 Gene-Editing Therapy Shows Early Promise for Dyslipidemia

ESC/EAS Stress Early LDL-Lowering in Select High-risk Patients

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

What’s Going to Be Hot at ESC Congress 2025?

Two siRNA Therapeutics Safely Lower Triglycerides in Mixed Hyperlipidemia

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Bridge-TIMI 73a: Olezarsen in patients with hypertriglyceridemia at high cardiovascular risk

Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT

New Biomarker Data Again Draw Eyes to Mineral Oil in REDUCE-IT

Reduction of Revascularization in Patients with Hypertriglyceridemia with Icosapent Ethyl: Insights from REDUCE-IT REVASC

EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl

REDUCE-IT: Prescription Fish Oil Prevents CV Events in Patients With High Triglycerides

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Nearly Half of Acute MI Patients Under Age 50 May Have Metabolic Syndrome

Will FDA’s Settlement With Amarin Weaken Agency Oversight of Off-Label Promotion?

新型反义抑制剂能够降低高甘油三酯水平

Un Nuevo Inhibidor Antisentido Reduce los Niveles Altos de Triglicéridos

Novel Antisense Inhibitor Cuts High Triglyceride Levels

Antisense Inhibition of Apolipoprotein C-III in Patients With Hypertriglyceridemia

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content